Literature DB >> 9663358

Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee.

M Wobig1, A Dickhut, R Maier, G Vetter.   

Abstract

Hylan G-F 20, which is derived from hyaluronan, is a highly purified, elastoviscous fluid with rheologic properties similar to those of synovial fluid in the knee joints of healthy young persons. The efficacy and safety of viscosupplementation with hylan G-F 20 were evaluated in a multicenter, double-masked clinical study in patients with chronic idiopathic osteoarthritis (OA) of the knee of 1 to 30 years' duration. Three intra-articular injections of 2 mL hylan G-F 20 were administered 1 week apart to 57 knees. The control group (60 knees) received 2 mL of physiologic buffered saline solution at the same intervals. Patients were predominantly female (65%), with a mean age of 62 years and mean weight of 76 kg. Using a visual analogue scale, patients assessed the following clinical variables: pain during weight-bearing, pain at rest during the night, reduction of pain during the most painful movement of the knee, and treatment success. Evaluators also assessed patients' loss of activity while performing difficult daily tasks and treatment success. There was dramatic early improvement in all six variables with hylan G-F 20 beginning after the first injection; the improvement continued through the study end points. The differences between hylan G-F 20 and saline treatment were statistically significant for all outcome measures. In the hylan G-F 20 group, 39% to 56% of patients were free or nearly free of weight-bearing pain 10 to 24 weeks after the last injection. Treatment with saline was less effective, with fewer than 13% of patients free or nearly free of weight-bearing pain. Use of rescue therapy was significantly greater in the saline group than in the hylan G-F 20 group. No adverse events were observed in the injected joint after hylan G-F 20 treatment. These results demonstrate that hylan G-F 20 is effective and well tolerated in the management of chronic idiopathic OA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663358     DOI: 10.1016/s0149-2918(98)80052-0

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  61 in total

Review 1.  Regular review: medical management of osteoarthritis.

Authors:  K Walker-Bone; K Javaid; N Arden; C Cooper
Journal:  BMJ       Date:  2000-10-14

2.  Non-surgical treatment of osteoarthritis: a half century of "advances".

Authors:  K D Brandt
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

Review 3.  Injections and return to play.

Authors:  Douglas P Dietzel; Eric C Hedlund
Journal:  Curr Pain Headache Rep       Date:  2005-02

Review 4.  Viscosupplementation for osteoarthritis: a primer for primary care physicians.

Authors:  M Carrington Reid
Journal:  Adv Ther       Date:  2013-11-08       Impact factor: 3.845

5.  EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation.

Authors:  Yves Henrotin; Xavier Chevalier; Raghu Raman; Pascal Richette; Jordi Montfort; Jörg Jerosch; Dominique Baron; Hervé Bard; Yannick Carrillon; Alberto Migliore; Thierry Conrozier
Journal:  Cartilage       Date:  2018-07-04       Impact factor: 4.634

6.  Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis.

Authors:  Alberto Migliore; Sandro Tormenta; Luis Severino Martin Martin; Costanzo Valente; Umberto Massafra; Mauro Granata; Andrea Alimonti
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

7.  Technologies for osteoarthritis of the knee: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01

8.  Efficacy of Hylan G-F 20 versus 6-methylprednisolone acetate in painful shoulder osteoarthritis: a retrospective controlled trial.

Authors:  Giovanni Merolla; John W Sperling; Paolo Paladini; Giuseppe Porcellini
Journal:  Musculoskelet Surg       Date:  2011-05-13

9.  Hylan g-f 20: review of its safety and efficacy in the management of joint pain in osteoarthritis.

Authors:  A Migliore; F Giovannangeli; M Granata; B Laganà
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2010-09-20

10.  Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.